Poor sleep in PCOS; Is melatonin the culprit?

Human Reproduction

Volumn 28, Issue 5, 2013, Pages 1348-1353

  Shreeve, N ^a   Cagampang, F ^b   Sadek, K ^b   Tolhurst, M ^a   Houldey, A ^a   Hill, C M ^b   Brook, N ^a   MacKlon, N ^a,b,c   Cheong, Y ^a,b,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c PRINCESS ANNE HOSPITAL   (United Kingdom)

Author keywords

melatonin; ovary; oxidative stress; PCOS; sleep

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; 8 HYDROXYDEOXYGUANOSINE; MELATONIN;

ADULT; AMENORRHEA; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPWORTH SLEEPINESS SCALE; FEMALE; HORMONE URINE LEVEL; HUMAN; NIGHT; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PITTSBURGH SLEEP QUALITY INDEX; SLEEP DEPRIVATION; SLEEP PATTERN; SLEEP QUALITY; URINALYSIS;

EID: 84876536740     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det013     Document Type: Article

References (32)

1. Adriaens I, Jacquet P, Cortvrindt R, Janssen K, Smitz J. Melatonin has dose-dependent effects on folliculogenesis, oocyte maturation capacity and steroidogenesis. Toxicology 2006;228: 333-343. (Pubitemid 44780795)
2. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index- A New Instrument for Psychiatric Practice and Research. Psychiatry Research 1989;28: 193-213. (Pubitemid 19144991)
3. Cagnacci A, Arangino S, Renzi A, Paoletti AM, Melis GB, Cagnacci P, Volpe A. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clin Endocrinol (Oxf) 2001;54: 339-346. (Pubitemid 32234198)
4. Cagnacci A, Soldani R, Yen SS. Exogenous melatonin enhances luteinizing hormone levels of women in the follicular but not in the luteal menstrual phase. Fertil Steril 1995;63: 996-999.
5. Cajochen C, Kräuchi K, Möri D, Graw P, Wirz-Justice A. Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis. Am J Physiol 1997;272: R1189-1196.
6. Cooke MS, Evans MD, Herbert KE, Lunec J. Urinary 8-oxo-2′- deoxyguanosine-source, significance and supplements. Free Radic Res 2000;32: 81-97.
7. Cooke MS, Evans MD, Dove R, Rozalski R, Gackowski D, Siomek A, Lunec J, Olinski R. DNA repair is responsible for the presence of oxidatively damaged DNA lesions in urine. Mutat Res. 2005;574: 58-66. (Pubitemid 40725968)
8. de Sousa G, Schlüter B, Buschatz D, Menke T, Trowitzsch E, Andler W, Reinehr T. A comparison of polysomnographic variablesbetween obese adolescents with polycystic ovarian syndromeand healthy, normal-weight and obese adolescents. Sleep Breath 2010;14: 33-38.
9. Gopal M, Duntley S, Uhles M, Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Med 2002;3: 401-4. (Pubitemid 35189927)
10. Johns MW. A new method for measuring daytime sleepiness-the Epworth Sleepiness Scale. Sleep 1991;14: 540-545.
11. Kayumov L, Casper RF, Hawa RJ, Perelman B, Chung SA, Sokalsky S, Shapiro CM. Blocking low-wavelength light prevents nocturnal melatonin suppression with no adverse effect on performance during simulated shift work. J Clin Endocrinol Metab 2005;90: 2755-2761. (Pubitemid 40686320)
12. Karihtala P, Soini Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 2007; 115: 81-103. (Pubitemid 46208084)
13. Klerman H, St Hilaire MA, Kronauer RE, Gooley JJ, Gronfier C, Hull JT, Lockley SW, Santhi N, Wang W, Klerman EB. Analysis method and experimental conditions affect computed circadian phase from melatonin data. PLoS One 2012;7: e33836.
14. Kunz D, Mahlberg R, Müller C, Tilmann A, Bes F. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab 2004;89: 128-134. (Pubitemid 38183871)
15. Kuşçu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2009;88: 612-7.
16. Littner M, Kushida CA, Anderson WM, Bailey D, Berry RB, Davila DG, Hirshkowitz M, Kapen S, Kramer M, Loube D et al. Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the role of actigraphy in the study of sleep and circadian rhythms: an update for 2002-an American academy of sleep medicine report 4. Sleep 2003;26: 337-341. (Pubitemid 39610684)
17. Luboshitzky R, Qupti G, Ishay A, Shen-Orr Z, Futerman B, Linn S. Increased 6-sulfatoxymelatonin excretion in women with polycystic ovary syndrome. Fertil Steril 2001;76: 506-510.
18. Luboshitzky R, Shen-Orr Z, Herer P, Nave R. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: the effect of ethinyl estradiol-cyproterone acetate treatment. Gynecol Endocrinol 2003;17: 441-447. (Pubitemid 37548342)
19. Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 2004;25: 177-195. (Pubitemid 39642189)
20. McCrae CS, McNamara JP, Rowe MA, Dzierzewski JM, Dirk J, Marsiske M, Craggs JG. Sleep and affect in older adults: using multilevel modeling to examine daily associations. J Sleep Res 2008;17: 42-53. (Pubitemid 351239352)
21. Moreira S, Soares E, Tomaz G, Maranhão T, Azevedo G. Polycystic ovary syndrome: a psychosocial approach. ActaMed Port 2010;23: 237-242.
22. Pollak CP, Tryon WW, Nagaraja H, Dzwonczyk R. How accurately does wrist actigraphy identify the states of sleep and wakefulness? Sleep 2001; 24: 957-965. (Pubitemid 33116997)
23. Reiter RJ, Tan DX, Maldonado MD. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res 2005;39: 215-216. (Pubitemid 41140762)
24. Rios ER, Venǎncio ET, Rocha NF, Woods DJ, Vasconcelos S, Macedo D, Sousa FC, Fonteles MM. Melatonin: Pharmacological Aspects and Clinical Trends. Int J Neurosci 2012;120: 583-590.
25. Rönnberg L, Kauppila A, Leppäluoto J, Martikainen H, Vakkuri O. Circadian and Seasonal-Variation in Human Preovulatory Follicular-Fluid Melatonin Concentration. J Clin Endocrinol Metab 1990;71: 493-496.
26. Sathyapalan T, Shepherd J, Coady AM, Kilpatrick ES, Atkin S. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2012;97: 3951-5.
27. Shochat T, Haimov I, Lavie P. Melatonin-the key to the gate of sleep. Ann Med 1998;30: 109-114.
28. Stressmarq Biosciences Inc. 8-hydroxy-2-deoxyguanosine EIA Kit protocol. Canada: Stressmarq Biociences, Inc. 2008. http://www.stressmarq. com/Products/Kits/SKT-120-96.aspx.
29. Tamura H, Nakamura Y, Korkmaz A, Manchester LC, Tan DX, Sugino N, Reiter R. Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril 2009;92: 328-43.
30. Tasali E, Van Cauter E, Ehrmann DA. Polycystic ovary syndrome and obstructive sleep apnea. Sleep Med Clin 2008a;3: 37-46.
31. Tasali E, Van Cauter E. Polycystic ovary syndrome and obstructive sleep apnea. Sleep Med Clin 2008b;3: 37-46.
32. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001;86: 517-520. (Pubitemid 32207453)